July 18, 2024European Heart Journal - Cardiovascular Pharmacotherapy

Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial

View Full Paper

Ask AI

Bookmark

Platelet inhibition with ticagrelor 60 mg twice daily is non-inferior to standard 90 mg dosing in elderly acute coronary syndrome patients undergoing percutaneous coronary intervention.
Mean P2Y12 reaction units were 26.4 with 60 mg versus 30.4 with 90 mg ticagrelor, confirming non-inferiority with significantly lower plasma drug levels (P = 0.006).
Randomized crossover trial in 50 elderly patients demonstrates that lower-dose ticagrelor maintains effective pharmacodynamics, supporting tailored antiplatelet therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial shows ticagrelor 60 mg achieves non-inferior platelet inhibition compared to 90 mg in elderly patients, suggesting lower doses may offer effective antiplatelet action.

Cite This Study

Piccolo et al. (2024) studied this question.

synapsesocial.com/papers/68e5fda8b6db64358759119d https://doi.org/10.1093/ehjcvp/pvae054

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows ticagrelor 60 mg achieves non-inferior platelet inhibition compared to 90 mg in elderly patients, suggesting lower doses may offer effective antiplatelet action.

Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial

Key Points

Discussion

Implication

Cite This Study

Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider